Laferobion

Laferobion is a medicine with antitumor, immunomodulatory and antiviral properties. It has no toxic effect.

[ 1 ]

Indications Laferobion

The medicine is used in the combined treatment of the following pathologies:

• in newborns (this includes premature babies) - with acute respiratory viral infections, meningitis with sepsis, pneumonia and various intrauterine infections (such as chlamydia with mycoplasmosis and ureaplasmosis, herpes, systemic candidiasis and CMV);
• in pregnant women - with lesions of the urogenital tract (such as ureaplasmosis with chlamydia and mycoplasmosis, papillomavirus, CMV, trichomoniasis, thrush and gardnerellosis with genital herpes), pyelonephritis with bronchogenic pneumonia, chronic pulmonary diseases, acute respiratory viral infections, as well as hepatitis B or C;
• for hepatitis category C, B or D in a chronic degree (in children or adults), and in addition to this, for liver cirrhosis together with plasmapheresis and hemosorption procedures);
• for chronic hepatitis types C, B or D in children with oncology (leukemia or lymphogranulomatosis, as well as large neoplasms);
• in the acute stage of hepatitis type C in a child;
• for perinatal forms of hepatitis category C, B or CMV in infants under 1 year of age;
• in acute stages of hepatitis types C or B for adults;
• adults with acute respiratory viral infections or flu (this includes diseases that cause superinfection);
• for herpes on mucous membranes or skin;
• for papillomaviruses (anogenital or common warts, as well as keratoacanthomas).

At the same time, Laferobion has demonstrated good results in the treatment of:

• ARI together with influenza, insulin-dependent diabetes mellitus, and asthma in childhood;
• infectious lesions of bacterial or viral type - adults or children who are sick frequently and for a long time;
• herpes with chlamydia, CMV, ureaplasmosis and toxoplasmosis - in adults or children;
• dysbacteriosis and pyelonephritis with glomerulonephritis, duodenitis or gastritis in the chronic stage, caused by enteroviruses of meningitis (serous type), mumps and diphtheria, which has a localized nature - in children;
• juvenile rheumatoid arthritis;
• tick-borne meningeal encephalitis;
• having prostatitis of different origins;
• purulent complications that developed after surgery.

[ 2 ], [ 3 ]

Release form

It is released in the form of suppositories, lyophilisate, and nasal powder.

The pack contains 3.5 or 10 suppositories in a blister.

The lyophilisate is contained in vials of 1,000,000, 5,000,000 or 3,000,000 IU, with 10 vials per pack. The vial may also have a volume of 6,000,000, 9,000,000 or 18,000,000 IU, with 1 vial per pack. The medicine may be supplied with injection fluid in ampoules (1 or 5 ml) – the number of these ampoules corresponds to the number of vials in the pack.

The nasal powder is available in 500,000 IU dropper bottles, 1 in a pack. Or in 100,000 IU dropper bottles, 10 in a pack.

Pharmacodynamics

After the drug is administered, the interferon substance reacts with specific conductors on the cell walls, thereby activating various intracellular reactions. Among these are the production of proteins, inhibition of cell proliferation processes, stimulation of the activity of phagocytes with macrophages, as well as lymphocytes in relation to target cells. At the same time, the drug inhibits viral replication inside cells affected by the infection.

Pharmacokinetics

The peak level of the drug inside the body after intramuscular or subcutaneous injection is observed after 3-12 hours after the procedure. The half-life is 3 hours.

Dosing and administration

Suppositories must be administered rectally.

The drug solution is administered intramuscularly or intravenously, and also by endolymphatic, intra-abdominal, rectal, intravesical, parabulbar or subconjunctival methods. In addition, it is used in the form of nasal drops and a solution administered through a nebulizer. Injections are often administered using 1,000,000 IU ampoules.

Suppositories are administered to newborns and premature infants in the amount of 150,000 IU. Children are required to administer 1 suppository twice a day at intervals of 12 hours. This course continues for 5 days.

When using the medication in combination in newborns with pneumonia of bacterial origin, 150,000 IU is used daily - 1 suppository three times a day for 7 days.

For infants aged 4-6 months, 1 suppository of 500,000 IU is administered twice a day, and for children over six months, 2 suppositories of 500,000 IU are administered 2 times a day.

During combination therapy for children with hepatitis B, C, and D (chronic type), 3,000,000 IU IFN/m2 of body area per day is prescribed ^. The drug is prescribed daily in the amount of 1 suppository (2 administrations per day) for 10 days and then according to a similar scheme with use every other day for 0.5-1 year. The duration of the course is prescribed taking into account laboratory and drug data.

In combined treatment of acute stages of hepatitis types B or C (for adults), the drug is used in the amount of 3,000,000 or 1,000,000 IU at the stage of long recovery or during a prolonged course of the disease. Also, 1 suppository is administered 2 times a day with a frequency of every other day. The therapy lasts for 4-6 months.

During the elimination of hepatitis of viral origin (in the chronic stage) in adult patients, doses of 3,000,000 or 1,000,000 IU are used daily - 1 suppository is administered 2 times a day for 1.5 weeks. Then, for six months, use every other day (if it is hepatitis type C) or every other day during the first year (if it is hepatitis type B).

In the process of complex therapy for influenza or acute respiratory viral infections (for adults), suppositories in the amount of 500,000 IU are used 1-2 times a day for 5 days.

Complex therapy for severe stages of influenza or acute respiratory viral infections (for children aged 1-7 years) involves the use of 500,000 IU suppositories, and for children aged 7-14 years – 1,000,000 IU suppositories. In such cases, the course lasts 5 days – 1 suppository 2 times a day.

To eliminate pyelonephritis, suppositories of 150,000 IU are required - insert 1 piece 2 times a day for 7 days, and then 2 suppositories per day (1 time in 3 days) for 1 month.

Nasal solution is most effective to use at the initial stage of the disease. To eliminate pathologies of viral-bacterial origin and ARVI, nasal drops, inhalations, and also spray are used.

For instillation, 5 drops of solution (dose 50,000-100,000 IU) are sufficient, which are introduced into both nostrils at least 6 times a day at intervals of 1.5-2 hours. Such therapy continues for at least 2-3 days. Inhalations are also highly effective.

The injection solution is available ready-made or as a lyophilisate, from which it can be made independently.

The powder in ampoules must be diluted using injection liquid - 1 ml is enough.

To treat the acute stage of hepatitis category B, an injection of 1,000,000 IU of the solution is required (administered 2 times a day) for 6 days, after which the dosage is reduced - the same portion is administered, but once a day, for 5 days. It is prohibited to use the drug if the patient has hepatic coma or cholestatic hepatitis.

If the above disease is chronic, it is necessary to administer 3-6 million IU once a day with a frequency of every other day. Such a course lasts a maximum of 24 weeks.

To get rid of tick-borne encephalitis, 1-3 million IU of the drug is used 2 times a day for 10 days, after which maintenance therapy is performed - the same dosage, but it is administered once at intervals of 1 day for 10 days.

Treatment of oncological pathologies involves the use of the maximum possible doses. Laferobion has an exclusively cytostatic effect, which is why it must be used after the regression of the tumor or when the patient goes into remission.

During the treatment of chronic myelogenous leukemia, 9,000,000 IU is prescribed to be used every day until remission is achieved, after which maintenance doses are used: the same dose, but used every other day.

To eliminate lymphocytic leukemia, it is necessary to use 3,000,000 IU of the drug daily until improvement occurs, and then switch to maintenance therapy - administer the same dose three times a week.

In the treatment of Kaposi's angiosarcoma, 36 million IU are administered daily over a long period of time. To stabilize the condition, the patient is transferred to maintenance doses: 18 million IU three times a week.

[ 4 ]

Use Laferobion during pregnancy

Pregnant or nursing mothers are prohibited from using Laferobion. If treatment with drugs is necessary, it is necessary to be guided by the balance of benefits for the woman and the risk of complications for the fetus.

Contraindications

Among the contraindications:

• intolerance to α-interferon or other components of the drug;
• autoimmune hepatitis;
• decompensated liver pathologies;
• CC values less than 50 ml/minute;
• history of hemoglobinopathy.

Side effects Laferobion

The use of the drug can cause the development of some side effects:

• development of flu-like symptoms: myalgia, chills, fever, asthenia, severe dizziness, pain in the eyes, fatigue and headaches;
• systemic disorders: dehydration, allergic symptoms, hyperglycemia, feeling of weakness, hypercalcemia, lymphadenitis with lymphadenopathy, and in addition hypothermia, peripheral edema and superficial phlebitis;
• damage to the hematopoietic system: development of anemia, thrombocytopenia, neutro-, leukopenia or granulocytopenia, and in addition lymphocytosis;
• reactions from the cardiovascular system: the appearance of angina pectoris, extrasystole, arrhythmia, bradycardia with tachycardia, and in addition to this, ventricular fibrillation and a decrease in blood pressure;
• endocrine dysfunction: development of hyper- or hypothyroidism, and in addition virilism or gynecomastia;
• disorders in the functioning of the hepatobiliary system: development of hepatitis or hyperbilirubinemia, as well as an increase in LDH and liver enzyme levels;
• gastrointestinal dysfunction: development of gingivitis or anorexia, appearance of abdominal pain, vomiting, dyspeptic symptoms, nausea and diarrhea;
• lesions in the musculoskeletal system: development of hyporeflexia, spondylitis and arthrosis with arthritis, as well as tendinitis, polyarteritis nodosa and muscle atrophy, as well as the appearance of cramps;
• disorders of the genitourinary system: development of impotence, amenorrhea or dysmenorrhea, as well as problems with urination;
• Mental disorders and problems with the nervous system: development of apathy, depression, migraine, tremor, aphasia, polyneuropathy and amnesia. Paresthesia, sleep disorders, problems with coordination and gait, hyperesthesia, extrapyramidal symptoms, a feeling of excitement and dizziness also appear;
• damage to the respiratory system: the appearance of rhinitis, cough and shortness of breath;
• skin problems: itching, development of dermatitis or alopecia.

Overdose

Due to Laferobion intoxication, disturbances of consciousness, lethargy and a feeling of prostration may occur. These symptoms are reversible and disappear after discontinuation of the drug.

Interactions with other drugs

Laferobion can be combined with any drugs that are often used during the treatment of the diseases described above (antibiotics, corticosteroids, chemotherapy drugs, immunosuppressants, as well as interferon inducers).

[ 5 ], [ 6 ]

Storage conditions

Laferobion should be kept out of the reach of small children. The medicine is usually stored in the refrigerator to maintain the temperature limits: 2-8 ^o C.

Special instructions

Reviews

Laferobion in all forms of production usually has either positive or neutral reviews. Parents who used the drug for their children during combined treatment for flu, acute respiratory viral infections, and other pathologies also speak well of it.

Shelf life

Laferobion can be used for 3 years from the date of release of the medicine. The prepared powder solution can be stored for a maximum of 1 day.